Inactivated vaccine for preventing mycoplasma gallisepticum and preparation method thereof

The killed Mycoplasma gallisepticum vaccine, prepared with specific strain CVCC3616 and adjuvants, effectively addresses the challenge of chicken mycoplasmosis by enhancing immune response and reducing disease incidence in poultry.

CN119679928APending Publication Date: 2025-03-25HOWWAY BIOTECHNOLOGY CO LTD
0 Cites 0 Cited by

Patent Information

Application Number
CN202411854911.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-12-17
Publication Date
2025-03-25

AI Technical Summary

Technical Problem

Chicken mycoplasmosis, caused by Mycoplasma gallisepticum, leads to chronic respiratory disease in chickens, increasing mortality rates, reducing egg production, and prolonging growth periods, posing significant economic threats to poultry farming due to high infection rates and secondary diseases.

Method used

A killed vaccine for Mycoplasma gallisepticum, comprising a specific strain (CVCC3616) with an antigen content of at least 2×10^9 CCU/mL, prepared through a process involving cultivation, concentration, inactivation with formaldehyde, and emulsification with adjuvants, enhancing immune response.

Benefits of technology

The vaccine significantly boosts the immune system of chickens, effectively preventing Mycoplasma gallisepticum infection, demonstrated by improved protection rates in experimental trials.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention relates to an inactivated vaccine for preventing mycoplasma gallisepticum and a preparation method thereof. Comprising an antigen and a vaccine adjuvant, the antigen is an inactivated mycoplasma gallisepticum CR strain which is purchased from the Chinese veterinary drug supervision institute and is numbered as CVCC3616, and the antigen content in each milliliter of the inactivated vaccine is not lower than 2 * 10 < 9 > CCU / mL. The preparation method comprises the following steps: S1, inoculating mycoplasma gallisepticum into a finished product culture medium according to a proportion of 10-20%, carrying out shake culture at 37 DEG C for 18-30 hours, harvesting a bacterial solution as a first-generation seed solution, and gradually expanding to the required content of the vaccine; s2, concentrating the mycoplasma gallisepticum culture bacterial liquid by using an ultrafiltration concentration method to obtain a mycoplasma gallisepticum antigen liquid; s3, preparing an oil phase and a water phase for later use; and emulsifying the oil phase and the water phase according to a volume ratio of 2: 1 to obtain the mycoplasma gallisepticum inactivated vaccine. The invention provides an inactivated vaccine for preventing mycoplasma gallisepticum and a preparation method of the inactivated vaccine, which can obviously improve the immunocompetence of chicken bodies and improve the prevention effect on mycoplasma gallisepticum.
Need to check novelty before this filing date? Find Prior Art